What does Remedy Plan Therapeutics do?
Remedy Plan Therapeutics is a Gaithersburg, MD-based clinical-stage pharmaceutical company focused on developing innovative, hyperbolic NAMPT inhibitors. Its approach aims to mitigate the severe toxicities seen with traditional NAMPT inhibitors while selectively targeting diseased cells involved in oncology, autoimmunity, and metabolic disorders.
How much did they raise?
The company raised $18M in financing from investors including lead backers Schooner Capital and Alexandria Venture Investments, along with other existing investors. This funding round, although not tied to a specific series, provides significant capital to support their clinical development efforts.
What are their plans for the money?
With the new capital, Remedy Plan Therapeutics plans to accelerate the advancement of its lead candidate, RPT1G, into Phase 1/2 clinical trials. This move is expected to significantly impact the treatment landscape for acute myeloid leukemia and high-risk myelodysplastic syndromes by providing a potentially safer and more effective therapeutic option.
What have they achieved so far?
The company has already made notable progress by developing a novel approach to NAMPT inhibition that avoids complete shutdown of NAMPT activity, thereby reducing on-target toxicity in healthy tissue while effectively inhibiting diseased cells.
